Excerpt from
article:
"Over 10% of the
biotechnology products currently in the pipeline target
high-risk infectious agents such as HIV and TB. As this type
of drug research ramps up, biopharmaceutical companies are
becoming increasingly sensitive to the dangers that accompany
handing these agents..."